Our PGY-2, Joshua Fein, is listed as the first author and was accepted for an oral presentation this year at the American Society of Hematology (ASH)! His presentation is entitled: Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogenic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT.

What an INCREDIBLE accomplishment, Dr. Fein!